MHRA’s Rawlins Plans British Version Of FDA’s Reg Science Centers
Executive Summary
The head of UK agency wants Britain to get its own version of the FDA’s Centers of Excellence in Regulatory Science and Innovation network to promote collaborations between it and academia to advance regulatory science through research, education, and scientific exchanges.
You may also be interested in...
Few UK "Promising Innovative Medicine" Holders Seek Joint MHRA/NICE Advice – Rawlins
MHRA chief says too few drug makers granted PIM designation on the basis of early clinical data are making use of joint consultations with the agency and the cost-effectiveness watchdog NICE.
Few UK "Promising Innovative Medicine" Holders Seek Joint MHRA/NICE Advice – Rawlins
MHRA chief says too few drug makers granted PIM designation on the basis of early clinical data are making use of joint consultations with the agency and the cost-effectiveness watchdog NICE.
FDA’s Hamburg Says EMA Could Be Model For Global Regulatory Coalition
Outgoing commissioner urges authorities to move away “from an outdated paradigm of only working in our own jurisdiction” in speech at European Medicines Agency’s 20th anniversary meeting.